Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Safety and Pharmacokinetic Evaluation of Naringenin: Single Dose Escalation Randomized Double Blind Controlled Trial

NCT03582553 is registered in ClinicalTrials.gov with Pennington Biomedical Research Center as lead sponsor.

NCT NCT03582553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03582553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Safety and Pharmacokinetic Evaluation of Naringenin: Single Dose Escalation Randomized Double Blind Controlled Trial
Lead sponsor
Pennington Biomedical Research Center
Phase
Phase 1
Overall status
Completed
Start date
May 25, 2018
Completion date
September 28, 2018
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pharmacokinetics, safety issues